U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07498751) titled 'Phase I PK and Safety Study of Ondansetron Inhalation Powder' on March 11.
Brief Summary: The goal of this clinical trial is to learn if LPI-1503 (Ondansetron Inhalation Powder) can deliver ondansetron into blood through inhalation. It will also learn about the safety of LPI-1503. The main questions it aims to answer are:
Does ondansetron enter into blood after inhalation of LPI-1503? And if it does, how efficiently? how rapidly?
What medical problems do participants have when and after inhaling LPI-1503? Researchers will compare LPI-1503 to a placebo (a look-alike substance that contains no drug), and to orally swallowed and inj...